- Home
- EH vs CAPR Comparison
EH vs CAPR Comparison
Compare EH & CAPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EH
- CAPR
- Stock Information
- Founded
- EH 2014
- CAPR 2005
- Country
- EH China
- CAPR United States
- Employees
- EH N/A
- CAPR N/A
- Industry
- EH Military/Government/Technical
- CAPR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- EH Industrials
- CAPR Health Care
- Exchange
- EH Nasdaq
- CAPR Nasdaq
- Market Cap
- EH 1.1B
- CAPR 867.6M
- IPO Year
- EH 2019
- CAPR N/A
- Fundamental
- Price
- EH $14.37
- CAPR $13.06
- Analyst Decision
- EH Buy
- CAPR Strong Buy
- Analyst Count
- EH 1
- CAPR 7
- Target Price
- EH $27.50
- CAPR $39.29
- AVG Volume (30 Days)
- EH 1.7M
- CAPR 1.5M
- Earning Date
- EH 11-18-2024
- CAPR 11-13-2024
- Dividend Yield
- EH N/A
- CAPR N/A
- EPS Growth
- EH N/A
- CAPR N/A
- EPS
- EH N/A
- CAPR N/A
- Revenue
- EH $49,679,663.00
- CAPR $23,228,045.00
- Revenue This Year
- EH N/A
- CAPR N/A
- Revenue Next Year
- EH $97.81
- CAPR $74.85
- P/E Ratio
- EH N/A
- CAPR N/A
- Revenue Growth
- EH 355.50
- CAPR 65.33
- 52 Week Low
- EH $9.51
- CAPR $3.52
- 52 Week High
- EH $22.98
- CAPR $23.40
- Technical
- Relative Strength Index (RSI)
- EH 44.57
- CAPR 37.54
- Support Level
- EH $14.16
- CAPR $13.00
- Resistance Level
- EH $16.93
- CAPR $20.75
- Average True Range (ATR)
- EH 0.68
- CAPR 1.60
- MACD
- EH -0.04
- CAPR -0.30
- Stochastic Oscillator
- EH 16.61
- CAPR 11.04
About EH EHang Holdings Limited ADS
EHang Holdings Ltd is an autonomous aerial vehicle (AAV) technology platform company. It focuses on making safe, autonomous and eco-friendly air mobility accessible to everyone. EHang provides customers in various industries with AAV products and commercial solutions: air mobility (including passenger transportation and logistics), smart city management and aerial media solutions. As the forerunner of cutting-edge AAV technologies and commercial solutions in the global Urban Air Mobility industry, it continues to explore the boundaries of the sky to make flying technologies benefit life in smart cities.
About CAPR Capricor Therapeutics Inc.
Capricor Therapeutics Inc is a biotechnology company focused on advancing transformative cell and exosome-based therapeutics to redefine the treatment landscape for rare diseases. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat and prevent a wide range of diseases with targeted delivery.